ALZHEIMERS DRUGS MARKET ANALYSIS

Global Alzheimer's drugs market growth can be hampered by extremely high cost associated with research and development of new drugs for this disease. Alzheimer's is a complex disorder with an unknown cause and unclear pathogenesis. Developing effective drugs requires huge investments in basic research to understand the disease mechanism first, followed by lengthy and expensive clinical trials. Since currently approved drugs only provide modest symptomatic benefits and do not slow progression, pharmaceutical companies have struggled to recoup their R&D costs through sales of these drugs. This high risk and uncertainty poses a significant hurdle for pharma companies and deters much needed investments in Alzheimer's drug innovation. Unless ways are found to share costs and risks across stakeholders, or returns are improved through premium pricing, this challenge will hamper growth of the Alzheimer's drugs market.

Market Opportunities: Growth in Geriatric Population

 Growth of  geriatric population worldwide can offer opportunities for the Alzheimer's drugs market growth. Alzheimer's is a disease that affects older adults, with risks rising sharply after age of 65. As average lifespans increase across both developed and developing nations, there will increase in number of people aged 65 years and over.  Since elderly population is the primary patient segment, any growth in this demography directly translates to a larger potential patient pool for Alzheimer's drugs. If effective treatments become available that can delay onset or slow progression of the disease, the Alzheimer's drugs market will be well poised to tap into this expanding pool of elderly patients. Industry players should focus on addressing the needs of an aging society to capitalize on this opportunity for future market growth.